With RxData, conduct your analogue analysis with peace of mind! Clear information with holistic views of key product life-cycle events:
With live monitoring of more than 100 data sources, RxData is the most complete repository of market access intelligence. RxData has detailed market access information presented in a simple way.
Better assess and predict coverage across U.S. payer types:
Better evaluate global decisions:
With RxData, go-to-market faster:
Phase 2/3 Transition (1)
Company A has a small molecule that has demonstrated activity across a range of tumors in Phase 2 and is finalizing Phase 3 strategy. Ultimately the company is looking to maximize lifetime value of the asset. The company intends to model the value of each potential indication (accounting for potential price, size of opportunity and competitive intensity) and then analyze whether lifetime value is enhanced by sequencing smaller but higher priced indications first vs. focusing on the largest potential indication.